why choose us

300×250 Ad Slot

Drug FDA Status

Showing 10 of 161 result(s) (Page 1 of 17)
Drug Name: Idvynso

Active Ingredient: doravirine and islatravir

Approval Date: 2026-04-20

Description: To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine

Drug Name: Foundayo

Active Ingredient: orforglipron

Approval Date: 2026-04-01

Description: To reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity

Drug Name: Awiqli

Active Ingredient: insulin icodec-abae

Approval Date: 2026-03-26

Description: To improve glycemic control in adults with type 2 diabetes mellitus

Drug Name: Lifyorli

Active Ingredient: relacorilant

Approval Date: 2026-03-25

Description: To treat platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic treatment regimens, at least one of which included bevacizumab

Drug Name: Avlayah

Active Ingredient: tividenofusp alfa-eknm

Approval Date: 2026-03-24

Description: To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)

Drug Name: Lynavoy

Active Ingredient: linerixibat

Approval Date: 2026-03-17

Description: To treat cholestatic pruritus associated with primary biliary cholangitis

Drug Name: Icotyde

Active Ingredient: icotrokinra

Approval Date: 2026-03-17

Description: To treat moderate-to-severe plaque psoriasis in patients 12 years and older who weigh at least 40 kg and who are candidates for systemic therapy or phototherapy

Drug Name: Yuviwel

Active Ingredient: navepegritide

Approval Date: 2026-02-27

Description: To increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses

Drug Name: Loargys

Active Ingredient: pegzilarginase-nbln

Approval Date: 2026-02-23

Description: To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction

Drug Name: Bysanti

Active Ingredient: milsaperidone

Approval Date: 2026-02-20

Description: To treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder

300×250 Ad Slot